Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-country, Multicenter, Single-arm, Open-label Study to Document the Safety, Tolerability and Effect of Alirocumab on Atherogenic Lipoproteins in High Cardio-vascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies

Next Previous
Trial Profile

A Multi-country, Multicenter, Single-arm, Open-label Study to Document the Safety, Tolerability and Effect of Alirocumab on Atherogenic Lipoproteins in High Cardio-vascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alirocumab (Primary) ; Atorvastatin; Ezetimibe; Rosuvastatin; Simvastatin
  • Indications Hypercholesterolaemia; Hyperlipoproteinaemia type IIa
  • Focus Adverse reactions; Registrational
  • Acronyms APPRISE; ODYSSEY APPRISE
  • Sponsors Sanofi

Most Recent Events

  • 01 Jan 2023 Results evaluating lipid-lowering efficacy and safety of alirocumab in a real-life setting in France, published in the Archives of Cardiovascular Diseases
  • 01 Nov 2022 Results of sub-group analysis assessing efficacy and safety of alirocumab in patients with hypercholesterolemia and high CV risk in a real-life setting, published in the Nutrition, Metabolism and Cardiovascular Diseases.
  • 22 Sep 2021 Results (n=68) of an analysis from Belgian cohort of this trial published in the International Journal of Clinical Practice

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top